Skip to content


Kevzara (sarilumab) is an antibody pharmaceutical. Sarilumab was first approved as Kevzara on 2017-05-22. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against interleukin-6 receptor subunit alpha.
Trade Name Kevzara
Common Name Sarilumab
Indication rheumatoid arthritis
Drug Class Monoclonal antibodies: fully human, immunomodulating
Get full access now